IMPACT OF REMIBRUTINIB TREATMENT ON WORKPLACE PRODUCTIVITY DUE TO CHRONIC SPONTANEOUS URTICARIA (CSU): A CANADIAN PRIVATE PAYOR PERSPECTIVE
Author(s)
Mondher Mtibaa, MSc1, Kaiwan Raza, BSc1, Ana Teresa Paquete, MSc2, Mark P. Connolly, BA, MSc, PhD3, Khalid Siddiqui, PhD4.
1Novartis Canada, Montreal, QC, Canada, 2Global Market Access Solutions LLC, Lisbon, Portugal, 3Global Market Access Solutions LLC, Mooresville, NC, USA, 4Novartis Pharma UK Ltd, London, United Kingdom.
1Novartis Canada, Montreal, QC, Canada, 2Global Market Access Solutions LLC, Lisbon, Portugal, 3Global Market Access Solutions LLC, Mooresville, NC, USA, 4Novartis Pharma UK Ltd, London, United Kingdom.
OBJECTIVES: Chronic spontaneous urticaria (CSU) is an inflammatory skin condition that affects individuals during prime working years. People with CSU with inadequate response to H1-antihistamines (H1-AHs) experience absenteeism and presenteeism driven by uncontrolled symptoms, fatigue, sleep disturbances, anxiety, and depression. The objectives of this study are to estimate annual productivity burden among employed Canadians with symptomatic CSU despite H1-AHs, and benefits with remibrutinib coverage.
METHODS: A static, prevalence-based model estimated annual workdays lost (absenteeism, short-term disability) and reduced productivity (presenteeism) in people with CSU. All inputs and estimates were based on 2025 data sources. CSU prevalence was applied to Canadian working age population and modelled for patients receiving H1-AHs that remained symptomatic. Using a fiscal modelling framework, Canadian age- and gender-specific employment rates and working hours were combined with baseline absenteeism and presenteeism rates from REMIX-1/-2 trials, to estimate the productivity burden from symptomatic CSU. Short-term disability (defined as >5 consecutive days off work) incidence and duration were based on published literature. Impact of remibrutinib was based on Work and Productivity and Activity Impairment (WPAI) changes on absenteeism and presenteeism from baseline to week 52 in REMIX-1/-2 trials. Scenarios with and without remibrutinib were compared.
RESULTS: Symptomatic CSU despite H1-AH treatment is estimated to account for 892,029 lost workdays and 4.8 million days of reduced-productivity annually, corresponding to 24 lost workdays and 130 days of reduced-productivity workdays per treated worker. With remibrutinib coverage, the productivity burden was reduced to 296,696 lost workdays and 1.47 million days of reduced-productivity annually, corresponding to 8 workdays lost and 40 days of reduced- productivity workdays per treated worker.
CONCLUSIONS: Symptomatic CSU despite H1-AHs imposes a substantial productivity burden in Canada. Introducing remibrutinib coverage is expected to reduce productivity burden by 69% overall, supporting the economic value of remibrutinib for employers and private payers.
METHODS: A static, prevalence-based model estimated annual workdays lost (absenteeism, short-term disability) and reduced productivity (presenteeism) in people with CSU. All inputs and estimates were based on 2025 data sources. CSU prevalence was applied to Canadian working age population and modelled for patients receiving H1-AHs that remained symptomatic. Using a fiscal modelling framework, Canadian age- and gender-specific employment rates and working hours were combined with baseline absenteeism and presenteeism rates from REMIX-1/-2 trials, to estimate the productivity burden from symptomatic CSU. Short-term disability (defined as >5 consecutive days off work) incidence and duration were based on published literature. Impact of remibrutinib was based on Work and Productivity and Activity Impairment (WPAI) changes on absenteeism and presenteeism from baseline to week 52 in REMIX-1/-2 trials. Scenarios with and without remibrutinib were compared.
RESULTS: Symptomatic CSU despite H1-AH treatment is estimated to account for 892,029 lost workdays and 4.8 million days of reduced-productivity annually, corresponding to 24 lost workdays and 130 days of reduced-productivity workdays per treated worker. With remibrutinib coverage, the productivity burden was reduced to 296,696 lost workdays and 1.47 million days of reduced-productivity annually, corresponding to 8 workdays lost and 40 days of reduced- productivity workdays per treated worker.
CONCLUSIONS: Symptomatic CSU despite H1-AHs imposes a substantial productivity burden in Canada. Introducing remibrutinib coverage is expected to reduce productivity burden by 69% overall, supporting the economic value of remibrutinib for employers and private payers.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE427
Topic
Economic Evaluation
Topic Subcategory
Work & Home Productivity - Indirect Costs
Disease
Sensory System Disorders (Ear, Eye, Dental, Skin)